09/21/2026
My podcast with Rich and Matt from Tick Bootcamp just went live. We discuss my finding Alzheimer's biomarkers in chronic Lyme patients and what the implications are regarding diagnosing and treating MSIDS factors and how these potentially can improve cognition. Here is a one minute teaser (they grilled me for hours!!)
https://drive.google.com/file/d/1fvTrFqxU_gNB2t-lRaowwdzEMoTv0EWm/view?pli=1
Here is the actual episode to watch:
https://tickbootcamp.com/episode-580-can-treating-lyme-disease-reverse-alzheimers-biomarkers-dr-richard-horowitzs-new-study/
The highlights: Could Lyme disease and other chronic inflammatory triggers play a role in Alzheimer’s disease—and could addressing those underlying factors change measurable Alzheimer’s biomarkers?
In this episode of the Tick Boot Camp Podcast, Dr. Richard Horowitz returns to discuss a provocative new case report he published exploring the relationship between Lyme disease, neuroinflammation, Alzheimer’s disease biomarkers, and dapsone combination therapy.
The conversation centers on a patient with a long history of Lyme disease who had an elevated phosphorylated tau 217 (p-tau217) level, an increasingly important blood biomarker associated with Alzheimer’s disease. After completing a nine-week dapsone combination protocol, the patient’s p-tau217 declined by approximately 63% and returned to the normal range. Her amyloid-beta 42/40 ratio also moved in a favorable direction, and she reported improved cognitive clarity.
This case provides a new research question: Could infections, toxins, metabolic dysfunction, sleep disorders, microbiome disturbances, and other inflammatory drivers contribute to Alzheimer’s pathology in subsets of patients—and could identifying and addressing those drivers change the course of the disease?
You can see other episodes that I did with Rich and Matt here:
https://tickbootcamp.com/dr-richard-horowitz-md/
